Full-Time

Program Manager

Posted on 8/8/2024

Abata Therapeutics

Abata Therapeutics

11-50 employees

Develops therapies for autoimmune diseases

No salary listed

Senior, Expert

Belmont, MA, USA

This is an on-site position based in the Watertown, MA office and the employee will be required to work in the office on a regular basis.

Category
Lab & Research
Life Sciences
Required Skills
Management
Requirements
  • Bachelor’s degree or higher in Biology, Chemistry, Microbiology, Life Sciences, or an equivalent scientific discipline
  • 5+ years’ experience in Program Management or related function, across various stages of drug development, with proven track record of success managing multiple projects/priorities
  • Prior experience managing and working with cross-functional teams in a matrix environment
  • Prior experience in a consulting firm (BCG, etc.) is a plus
  • Travel: 0-10%
Responsibilities
  • Manage, optimize, track, and coordinate multiple workstreams across research, clinical, and technical operations to ensure key objectives and milestones are met
  • Build relationships and work cross-functionally with key stakeholders (Executive management, Program Team Leads, functional leads, external vendors and partners) to ensure alignment and drive execution of functional and program objectives
  • Identify critical path activities, resource constraints, risks, and conflicts that could impact timelines
  • Develop and optimize program management tools and processes to ensure consistency across functions and programs
  • Maintain a current overview of program status, and clearly and pro-actively communicate progress
  • Thought partner with Program Team Leads (PTLs) enabling strategic messaging and framing of key program outputs both internally and externally
  • Prepare presentation materials and participate in team discussions.

Abata Therapeutics develops therapies for autoimmune diseases, focusing on type 1 diabetes. Their main product, ABA 201, is a Treg cell therapy aimed at patients with some remaining beta cell function. This therapy is currently in the IND enabling studies phase and is expected to enter clinical trials by 2025. Abata stands out in the biotech market by targeting a specific group of patients and forming strategic partnerships, such as with ElevateBio, to enhance their research and manufacturing capabilities. The company's goal is to improve patient outcomes through advanced treatments while fostering a collaborative work environment.

Company Size

11-50

Company Stage

Early VC

Total Funding

$190M

Headquarters

Cambridge, Massachusetts

Founded

2021

Simplify Jobs

Simplify's Take

What believers are saying

  • Recent investment from Bristol Myers Squibb boosts their Treg cell therapy pipeline.
  • Experienced leaders like Joanne Beck and Ellen Cahir-McFarland strengthen their R&D efforts.
  • Collaboration with ElevateBio ensures scalable, regulatory-compliant Treg production.

What critics are saying

  • Intensifying competition from companies like Sonoma Biotherapeutics may impact market share.
  • Stringent FDA regulations could delay clinical trials for cell therapies.
  • Rising clinical trial costs may strain Abata's financial resources for R&D.

What makes Abata Therapeutics unique

  • Abata focuses on Treg cell therapies for autoimmune diseases like MS and diabetes.
  • Their lead product, ABA 201, targets type 1 diabetes with remaining beta cell function.
  • Strategic partnerships, like with ElevateBio, enhance their manufacturing and development capabilities.

Help us improve and share your feedback! Did you find this helpful?

Growth & Insights and Company News

Headcount

6 month growth

5%

1 year growth

2%

2 year growth

7%
Golden State News Wire
Sep 16th, 2024
Abata Therapeutics Appoints Joanne Beck, Ph.D., as Chief Technical Officer

WATERTOWN, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) - Abata Therapeutics, a clinical-stage biotech company focused on transforming lives with Treg therapies for severe autoimmune and inflammatory diseases, today announced the appointment of Joanne Beck, Ph.D., as chief technical officer.

CityBiz
Aug 15th, 2024
Abata Therapeutics Announces Investment from Bristol Myers Squibb

WATERTOWN, Mass., Aug. 15, 2024 (GLOBE NEWSWIRE) — Abata Therapeutics, a company focused on transforming lives with Treg therapies for... Read More

Yahoo Finance
Aug 15th, 2024
Abata Therapeutics Announces Strategic Investment from Bristol Myers Squibb Supporting Advancement of its Treg Cell Therapy Pipeline into Clinical Development

Founded by pioneers in Treg biology, TCR and antigen discovery, disease pathogenesis, and molecular and imaging biomarkers, Abata has developed a differentiated product engine to create engineered Treg cell therapies that are tissue-specific, robust, and durable.

Benzinga
Apr 20th, 2023
Abata Therapeutics Announces the Appointment of Leonard Dragone, M.D., Ph.D., as Chief Medical Officer

Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients with severe autoimmune and inflammatory diseases, today announced the appointment of Leonard "Lenny" Dragone, M.D., Ph.D., as its new chief medical officer.

Multiple Sclerosis News Today
Dec 15th, 2022
1st Abata Candidate Is Treatment ABA-101 for Progressive MS | Now in Early Studies, MS Therapy Expected to Enter Trials in 2024 | Multiple Sclerosis News Today

Abata has collaborated with ElevateBio BaseCamp to develop a manufacturing process that engineers and grows Tregs for therapeutic use.

INACTIVE